Creatine was previously shown to produce an antidepressant-like effect in the tail suspension test through a modulation of the dopaminergic system. In this study, the mechanisms underlying its antidepressantlike effect were further evaluated by investigating the involvement of the serotonergic system in its effect. The anti-immobility effect of creatine (1 mg/kg) was prevented by the pretreatment of mice with p-chlorophenylalanine methyl ester (PCPA; 100 mg/kg, i.p., for 4 consecutive days, an inhibitor of serotonin (5-HT) synthesis). Creatine (0.01 mg/kg, sub-effective dose) in combination with sub-effective doses of WAY100635 (0.1 mg/kg, s.c., a 5-HT 1A receptor antagonist), 8-OH-DPAT (0.1 mg/kg, i.p., a 5-HT 1A receptor agonist) or selective serotonin reuptake inhibitors fluoxetine (5 mg/kg, p.o.), paroxetine (0.1 mg/kg, p.o.), citalopram (0.1 mg/kg, p.o.) and sertraline (3 mg/kg, p.o.) reduced the immobility time in the tail suspension test as compared with either drug alone. These results indicate that the antidepressant-like effect of creatine is likely mediated by an interaction with 5-HT 1A receptors. Of note, the present results also indicate that creatine improves the effectiveness of the selective serotonin reuptake inhibitors, a finding that may have therapeutic implications for the treatment of depressive disorders.
Introduction
Creatine, a substrate for cytosolic and mitochondrial creatine kinases, is a precursor of phosphocreatine (Andres et al., 2008) . The creatine kinase/phosphocreatine system seems to play a complex, multi-faceted role in brain energy homeostasis by maintaining high ADP levels at the site in mitochondria at which ATP is generated and low levels at the site of ATP utilization (Bessman and Carpenter, 1985; Wyss et al., 1992) . A growing number of reports have provided evidence for the importance of the creatine kinase/phosphocreatine system and creatine metabolism for maintaining energy homeostasis in brain. In addition, this system has been also implicated in the pathophysiology of depression, since: (i) brain phosphocreatine, detected by phosphorus-31 magnetic resonance spectroscopy, decreased in severely depressed patients (Kato et al., 1992) ; (ii) an inverse correlation between Hamilton Depression Rating Scale scores and white matter creatine levels was shown (Dager et al., 2004) ; (iii) single prolonged Abbreviations: ANOVA, analysis of variance; 8-OH-DPAT, (+)-8-hydroxy-2-(din-propylamino)tetralinHBr; FST, forced swimming test; 5-HT, serotonin; PCPA, pchlorophenylalanine methyl ester; SSRI, selective serotonin reuptake inhibitor; TST, tail suspension test; WAY100635, N-N-(2-pyridynyl) cyclohexanecarboxamide.stress and forced swimming stress decreased creatine concentrations in the rat prefrontal cortex (Herring et al., 2008; Kim et al., 2010; Knox et al., 2010) ; (iv) learned helplessness, a well validated animal model of depression, decreased the hippocampal creatine transporter expression as compared to wild type animals and the selective serotonin reuptake inhibitor escitalopram blocked this effect (Lugenbiel et al., 2010) ; (v) some antidepressants such as paroxetine and imipramine increase creatine kinase activity (Assis et al., 2009; Reus et al., 2012a,b; Santos et al., 2009); (vi) agents that exert antidepressant action cause changes in brain levels of creatine-containing compounds, such as S-adenosyl-l-methionine that, in turn, increases phosphocreatine brain levels (Papakostas, 2009; Papakostas et al., 2003; Silveri et al., 2003) .
Several clinical trials (Amital et al., 2006; Kondo et al., 2011; Lyoo et al., 2012) and studies with animal models (Allen et al., 2010 (Allen et al., , 2012 Cunha et al., 2012) have reported that creatine supplementation exerts antidepressant effects. Specifically, it was recently demonstrated that the administration of creatine produces an antidepressant-like effect in the tail suspension test, a predictive test of antidepressant properties frequently used to evaluate the efficacy of drugs designed to treat depression, and this effect was shown to be mediated by a dopaminergic activation (Cunha et al., 2012) . Taking into account that microdialysis studies have clearly shown that exposure of the striatum or nucleus accumbens to serotonin results in increased release of dopamine (Yadid et al., 1994; Dremencov et al., 2004) and that drugs that enhance serotonergic neurotransmission, such as those that inhibit serotonin reuptake at nerve terminals, or its metabolism (monoamine oxidase inhibitors) are effective in treating depression, in the present study the role of the serotonergic system in the antidepressant-like effect of creatine in the TST was investigated.
There is accumulating evidence for a critical involvement of serotonergic receptors, particularly 5-HT 1A , in the pathophysiology and treatment of depression (Hensler, 2002; Middlemiss et al., 2002) . In animal studies, 5-HT 1A agonists increase prefrontal dopamine release (Díaz-Mataix et al., 2005; Bantick et al., 2005) . Therefore, we hypothesized that 5-HT 1A receptors could be involved in the antidepressant-like effect of creatine in the TST.
Furthermore, another aim of this study was to investigate the possibility that the combined administration of sub-effective doses of creatine and serotonin reuptake inhibitors fluoxetine, paroxetine, citalopram and sertraline causes a synergistic antidepressant-like effect in the TST. This is an approach that has potential therapeutic relevance, considering that the clinical aim of combining selective serotonin reuptake inhibitors with a pharmacological agent is to increase the antidepressant efficacy while reducing side effects (Nelson, 2007) .
Materials and methods

Animals
Male Swiss mice (30-40 g, 60-75 days) were used in the present study. Mice were housed in groups of fourteen animals per plastic cage under controlled conditions of light (from 07:00 to 19:00 h) and temperature (21 ± 1
• C). Mice were allowed free access to standard laboratory food and tap water, and to adapt to the laboratory environment for at least 1 week before the behavioral studies. Each experimental group consisted of 8-10 animals. Animals were randomly distributed into specified experimental groups. All manipulations were carried out between 14:00 and 17:00 h, with each animal used only once. All procedures in this study were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Ethics Committee of the Institution. All efforts were made to minimize animals suffering and to reduce the number of animals used in the experiments.
Drugs
The following drugs were used: creatine monohydrate, p-chlorophenylalanine methyl ester (PCPA), N-N-(2-pyridynyl) cyclohexanecarboxamide (WAY100635), (+)-8-hydroxy-2-(di-n-propylamino)tetralinHBr (8-OH-DPAT) (Sigma Chemical Co., USA), fluoxetine hydrochloride, sertraline hydrochloride, paroxetine hydrochloride (Pfizer, Brazil), citalopram bromidrate (LIBBS Farmacêutica Ltda., Brazil). All drugs were dissolved in saline, except creatine, fluoxetine, sertraline, paroxetine, citalopram which were dissolved in distilled water. All drugs were administered by intraperitoneal (i.p.) route, except creatine, fluoxetine, sertraline, paroxetine and citalopram which were administered by oral route (p.o.) by gavage and WAY100635 that was administered by subcutaneous route (s.c.). All drugs were administered in a constant volume of 10 ml/kg body weight.
Experimental design
In order to investigate a possible contribution of the 5-HT system to the effect of creatine in reducing the immobility time in the TST, animals were pretreated with PCPA (100 mg/kg, i.p., an inhibitor of serotonin synthesis) or vehicle, once a day, for four consecutive days. Then, 24 h after the last PCPA or saline injection, animals were treated with creatine (1 mg/kg, p.o.), fluoxetine (10 mg/kg, p.o., a serotonin reuptake inhibitor, positive control) or vehicle and were tested in the TST open-field test 60 min later.
In another set of experiments, a sub-effective dose of creatine (0.01 mg/kg, p.o.) or vehicle was administered 30 min before administration of a sub-effective dose of 8-OH-DPAT (1 mg/kg, i.p., a 5-HT 1A receptor agonist), WAY100635 (0.1 mg/kg, s.c., a 5-HT 1A receptor antagonist) or vehicle. Thirty minutes later, the TST was carried out.
In order to investigate the potential synergistic effect of sub-effective doses of creatine with sub-effective doses of selective 5-HT reuptake inhibitors (fluoxetine, paroxetine, sertraline and citalopram) in the TST or open-field test, creatine or vehicle administration was followed by another immediate administration of the antidepressant drug or vehicle 60 min before the TST or open-field test.
In order to establish the effective and sub-effective doses of serotonin receptor agonist 8-OH-DPAT, mice were administered intraperitoneally with 8-OH-DPAT at doses 0.1-1 mg/kg and 30 min later were submitted to the TST or open-field test. In order to establish the effective and sub-effective doses of selective serotonin reuptake inhibitors, mice were administered orally with citalopram and sertraline at doses: 0.1-10 mg/kg and 3-30 mg/kg, respectively, and 60 min later were submitted to the TST or open-field test.
The effective (1 mg/kg) and subeffective (0.01 mg/kg) doses of creatine were selected on the basis of previous study from our laboratory (Cunha et al., 2012) and the doses of the serotonergic agents (PCPA, WAY 100635, 8-OH-DPAT, and the selective serotonin reuptake inhibitors) were selected on the basis of literature data and on previous results from our laboratory (Brocardo et al., 2008; Cunha et al., 2008; Kaster et al., 2005; Machado et al., 2009; O'Leary et al., 2007; O'Neill and Conway, 2001 ).
Behavioral tests 2.4.1. Tail suspension test (TST)
The TST has become one of the most widely used models for assessing antidepressant-like activity in mice. The test is based on the fact that animals subjected to the short-term inescapable stress of being suspended by their tail, will develop an immobile posture. The total duration of immobility induced by tail suspension was measured according to the method described by Steru et al. (1985) . Briefly, mice both acoustically and visually isolated were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Immobility time was recorded during a 6 min period. Mice were considered immobile only when they hung passively and completely motionless. The immobility time was recorded by observers blind to the drug treatment (Cunha et al., 2008; Machado et al., 2009 ).
Open-field test
To assess the possible effects of creatine on locomotor activity, mice were evaluated in the open-field paradigm as previously described by Machado et al. (2009) . Mice were individually placed in a wooden box (40 cm × 60 cm × 50 cm) with the floor divided into 12 equal rectangles. The number of rectangles crossed by the mice with its four paws (crossing) was registered during a period of 6 min. The number of crossings was considered as indicative of locomotor activity. The behavior was recorded by observers blind to the drug treatment.
Statistical analysis
Comparisons between experimental and control groups were performed by oneway (dose-response curve of 8-OH-DPAT, sertraline and citalopram) or two-way (investigation of serotonergic system modulation in the antidepressant-like effect of creatine) ANOVA followed by Tukey's HSD test when appropriate. A value of P < 0.05 was considered to be significant.
Results
Influence of pretreatment with PCPA on the effect of creatine in the TST and open-field test
The result depicted in Fig. 1A shows that creatine at the dose of 1 mg/kg, p.o. reduced the immobility time in the TST in mice pretreated with vehicle, confirming previous data from our group (Cunha et al., 2012) . Moreover, this anti-immobility effect of creatine (1 mg/kg, p.o.) was prevented by pretreatment of mice with the inhibitor of serotonin synthesis (100 mg/kg, i.p., for 4 consecutive days). A two-way ANOVA showed significant differences for PCPA treatment (F(1,43) = 43.33; P < 0.01), creatine treatment (F(2,43) = 4.79; P < 0.05) and PCPA × creatine treatment interaction (F(2,43) = 8.36; P < 0.01). The number of crossings in open-field test was not altered by the pretreatment with PCPA and creatine treatments (P > 0.05; Fig. 1B ).
Effect 8-OH-DPAT on the immobility time in the tail suspension test and on the number of crossings in the open-field test
The effect of acute administration of 8-OH-DPAT, a 5-HT 1 receptor agonist, at the dose range 0.1-1 mg/kg, i.p. on the immobility time in the TST is shown in Fig. 2A . This agonist administered at doses of 0.5-1 mg/kg reduced the immobility time (20.8% and 34.2% of reduction, respectively). However, 8-OH-DPAT administered at a dose of 0.1 mg/kg did not reduce the immobility time ( Fig. 2A) . The one-way ANOVA revealed a significant effect of 8-OH-DPAT treatment (F(3,34) = 11.45; P < 0.01). Considering this result, the sub-effective dose of 0.1 mg/kg was chosen to be used in the control group or either drug alone (Fig. 3A) . A two-way ANOVA showed significant differences for creatine treatment (F(1,32) = 19.35; P < 0.01), WAY100635 treatment (F(1,32) = 7.68; P < 0.05), and creatine × WAY100635 interaction (F(1,32) = 26.90; P < 0.01). The number of crossings in open-field test was not altered by the administration of creatine and/or WAY100635 (P > 0.05; Fig. 3C ).
The administration of 8-OH-DPAT at a sub-effective dose (0.1 mg/kg, i.p.) caused an antidepressant-like effect when combined with a sub-effective dose of creatine (0.01 mg/kg, p.o.), as compared to the control or either drug alone (Fig. 3B) . A twoway ANOVA showed significant differences for creatine treatment (F(1,29) = 11.32; P < 0.01), 8-OH-DPAT treatment (F(1,29) = 6.67; P < 0.05), and creatine × 8-OH-DPAT interaction (F(1,29) = 7.86; P < 0.05). The number of crossings in open-field test was not altered by the administration of creatine and/or 8-OH-DPAT (P > 0.05; Fig. 3D ). Citalopram administration by p.o. route at doses of 1 and 10 mg/kg reduced the immobility time in the TST in mice, but did not alter the immobility time when administered at a dose of 0.1 mg/kg (Fig. 4A) . The one-way ANOVA revealed a significant effect of citalopram treatment (F(3,28) = 17.20; P < 0.01). Sertraline at doses of 3 and 10 mg/kg did not affect the immobility time in the TST, but caused a reduction in the immobility time at dose of 30 mg/kg, p.o. (Fig. 4B) . The one-way ANOVA revealed a significant effect of sertraline treatment in mice (F(3,29) = 13.86; P < 0.01).
Furthermore, citalopram at the dose range 0.1-10 mg/kg, p.o. and sertraline (3-30 mg/kg, p.o.) were tested in the open-field test in mice. The administration of citalopram or sertraline did not alter the number of crossings in the open-field test (P > 0.05; Fig. 4C and D, respectively).
Effect of the interaction of creatine with selective serotonin reuptake inhibitors on the immobility time in the TST and on the number of crossings in the open-field test
Fluoxetine administered at a sub-effective dose (5 mg/kg, p.o.) exhibited a potent antidepressant-like effect when combined with a sub-effective dose of creatine (0.01 mg/kg, p.o.) in the TST as compared with the control or either drug alone (Fig. 5A) . A two-way ANOVA showed significant differences for fluoxetine treatment (F(1,29) = 22.22; P < 0.01), creatine treatment (F(1,29) = 6.73; P < 0.01) and fluoxetine × creatine interaction (F(1,29) = 10.71; P < 0.01). Moreover, the number of crossings in open-field test was not altered by the administration of creatine and/or fluoxetine (P > 0.05; Fig. 6A) .
Paroxetine administered at a sub-effective dose (0.1 mg/kg, p.o.) produced an antidepressant-like effect when combined with a sub-effective dose of creatine (0.01 mg/kg, p.o.) in the TST as compared with control or either drug alone (Fig. 5B) . A two-way ANOVA showed significant differences for paroxetine treatment (F(1,28) = 4.59; P < 0.05), creatine treatment (F(1,28) = 6.72; P < 0.05), and paroxetine × creatine interaction (F(1,28) = 6.24; P < 0.05). The number of crossings in open-field test was not altered by the administration of creatine and/or paroxetine (P > 0.05; Fig. 6B) .
Additionally, the selective serotonin reuptake inhibitor citalopram administered at a sub-effective dose (0.1 mg/kg, p.o.) exhibited antidepressant-like effect when combined with a subeffective dose of creatine (0.01 mg/kg, p.o.) in the TST as compared with the control group or either drug alone (Fig. 5C) . A two-way ANOVA showed significant differences for citalopram treatment (F(1,30) = 6.77; P < 0.01), creatine treatment (F(1,30) = 4.60; P < 0.05) and citalopram × creatine interaction (F(1,30) = 10.53; P < 0.05). The number of crossings in open-field test was not altered by the administration of creatine and/or citalopram (P > 0.05; Fig. 6C ). Fig. 6D shows that sertraline administered at a sub-effective dose (3 mg/kg, p.o.) caused an antidepressant-like effect when combined with a sub-effective dose of creatine (0.01 mg/kg, p.o.) in the TST as compared with control group or either drug alone (Fig. 6D) . A two-way ANOVA showed significant differences for sertraline treatment (F(1,32) = 29.42; P < 0.01), creatine treatment (F(1,32) = 10.06; P < 0.01), and sertraline × creatine interaction (F(1,32) = 5.23; P < 0.05). The number of crossings in open-field test was not altered by the administration of creatine and/or sertraline (P > 0.05; Fig. 6D ).
Discussion
The high prevalence of depression, the fact that a significant proportion of individuals do not respond well to any currently used antidepressant and the side effects elicited by these drugs support the need for new therapeutics to treat this disorder (Wong and Licinio, 2001) . In this context emerges creatine, a safe and well-tolerated dietary supplement that has been reported to exert antidepressant effects in animal models (Allen et al., 2010; Cunha et al., 2012) and clinical trials (Kondo et al., 2011; Lyoo et al., 2012) . Deregulations on the serotonergic system are implicated in the pathogenesis of depression and most of the currently available antidepressants cause activation of serotonergic neurotransmission (Elhwuegi, 2004; Millan, 2004) . Thus, we hypothesized that the antidepressant-like effect of creatine in the TST in mice could be mediated by an activation of the serotonergic system.
In the first set of experiments we investigated whether the pretreatment of mice with PCPA, an inhibitor of the enzyme tryptophan hydroxylase, was able to abolish the antidepressant-like effect of creatine in the TST. PCPA was reported to produce a significant depletion of cortical 5-HT content in rats (93%) and mice (67-70%) (Cesana et al., 1993; O'Leary et al., 2007; Page et al., 1999) . The results presented herein clearly show that the pretreatment of mice with PCPA abolished the anti-immobility effect of creatine and fluoxetine, a positive control, in the TST. The administration of PCPA at the same dose employed in the present study reversed the antidepressant-like action of fluoxetine in the forced swimming test (FST) (Brocardo et al., 2008; Kaster et al., 2005) and in TST (Machado et al., 2009; Rodrigues et al., 2002) , but was not able to reverse the antidepressant-like effect of imipramine in the TST (Rodrigues et al., 2002) . The reversal of the effect of creatine by the depletion of 5-HT elicited by PCPA suggests that the antidepressantlike effect of creatine is dependent on the bioavailability of 5-HT in the synaptic cleft, similar to fluoxetine. In line with this notion, creatine supplementation causes an antidepressant-like effect in the FST in rats by increasing swimming time, a behavioral profile associated with a serotonergic mechanism of action (Allen et al., 2010) . Furthermore, the treatment with acetyl-l-carnitine, compound endowed with antidepressant-like properties in the FST, increases the phosphocreatine and the phosphocreatine/creatine ratio associated with increases in the levels of 5-HT in the cerebral cortex of mice (Di Cesare Mannelli et al., 2011; Pulvirenti et al., 1990; Smeland et al., 2012) .
The 5-HT 1A receptor has been increasingly associated with alterations in mood and emotion and has opposing functions as a pre-synaptic somatodendritic autoreceptor and a post-synaptic heteroreceptor (Albert, 2012) . Indeed, the involvement of 5-HT 1A receptors in the mechanism of action of many classes of antidepressant drugs, including tricyclics, selective serotonin reuptake inhibitors and monoamine oxidase inhibitors have been shown (Hensler, 2002) . The blockade of 5-HT 1A autoreceptors enhances presynaptic serotonergic function by preventing self-inhibitory actions of 5-HT on the firing and release of serotonergic neurons, without hindering postsynaptic hippocampal responses that contribute to an antidepressant-like effect (Artigas et al., 1994 . Accordingly, clinical studies have demonstrated that the co-administration of a 5-HT 1A antagonist combined with selective serotonin reuptake inhibitors accelerates the onset of the antidepressant effect (Artigas et al., 1994) . The present results indicate an involvement of 5-HT 1A receptors in the antidepressant-like effect of creatine in the TST. The first piece of evidence to support this assumption is that the administration of WAY100635 potentiated the antidepressant-like action of a sub-effective dose of creatine in the TST. WAY100635 is a 5-HT 1A receptor antagonist that synergistically potentiates the increments of extracellular 5-HT produced by serotonergic antidepressants . In line with our findings, the combined administration of WAY100635 with a sub-effective dose of antidepressant compounds, including fluoxetine, significantly reduced the immobility time in the FST in rats (Tatarczynska et al., 2002) and mice (Brocardo et al., 2008; Kaster et al., 2005; Zomkowski et al., 2004) . One possibility that could account for the potentiation of the effect of creatine in the TST by WAY100635 is that the blockade of presynaptic 5-HT 1A autoreceptors with the consequent increase on 5-HT release caused by this antagonist could potentiate the likely increase on 5-HT availability induced by creatine, causing an antidepressant-like effect. Nevertheless, we should take into account that WAY100635 is currently described as a potent full agonist at the dopamine D 4 receptors, but it is tenfold selective in its affinity for 5-HT 1A receptors over dopamine D 4 receptors (Chemel et al., 2006) .
The postsynaptic 5-HT 1A heteroreceptors that are abundant receptors in the central nervous system mediate 5-HT actions on target neurons and have been implicated in regulation of mood, emotion and stress responses (Albert, 2012) . Here we show the 5-HT 1A receptor agonist 8-OH-DPAT administered at higher doses elicited an antidepressant-like effect in the TST, in agreement with the reported reduction in the immobility time caused by this agonist in the FST in mice and rats (Lopez-Rubalcava and Lucki, 2000; O'Neill and Conway, 2001) . Noteworthy, treatment with the serotonergic neurotoxins 5,7-dihydroxytryptamine or PCPA, which are proposed to act presynaptically, had no effect on the antiimmobility response of 8-OH-DPAT in the FST, suggesting that the postsynaptic 5-HT 1A receptors mediate the antidepressant-like effect of this agonist (Luscombe et al., 1993) . Moreover, 8-OH-DPAT has been shown to augment the activity of antidepressants in FST (Redrobe et al., 1996) , possibly via activation of post-synaptic 5-HT 1A receptors. Indeed, activation of postsynaptic 5-HT 1A receptors produces changes similar to those of conventional antidepressants (Lucki, 1991) . Taking these findings into account, the synergistic antidepressant-like effect observed when mice were treated with subeffective doses of creatine and 8-OH-DPAT suggest that an activation of postsynaptic 5-HT 1A receptors is likely implicated in the effect of creatine in the TST. It is possible to suppose that creatine activates some intracellular signaling pathways downstream to postsynaptic 5-HT 1A , as protein kinase C and extracellular-signalregulated kinases (Mogha et al., 2012 ), but we cannot rule out the possibility that creatine may directly interact with 5-HT 1A receptor. However, 8-OH-DPAT is also described as an agonist at the 5-HT 7 receptors (Sprouse et al., 2004) and as a serotonin reuptake inhibitor (Assié and Koek, 1996) , targets that may also mediate the antidepressant-like effect of creatine. The selective serotonin reuptake inhibitors are the antidepressants most prescribed all over the world (Stahl, 1998) , although their use cause side effects such as sexual dysfunction, sleepiness, and weight gain (Cascade et al., 2009 ). However, combinations of antidepressants with various substances may increase their efficacy while minimizing the side effects (Nelson, 2007) . In the present study, we investigated the effects of the combined oral administration of selective serotonin reuptake inhibitors with creatine, all at doses that per se produce no antidepressant-like effect in the TST. Interestingly, synergistic antidepressant-like effects of creatine with fluoxetine, paroxetine, citalopram and sertraline were shown. Accordingly, a recent study demonstrated that creatine produced a synergistic antidepressant-like effect with fluoxetine in the FST in rats (Allen et al., 2012) . Moreover, our finding is in line with a clinical study which reported that fluoxetine and creatine combined therapy with for eight weeks produced an increase in brain phosphocreatine concentration associated with a decline on the scores of depression rating scale in female adolescents with selective serotonin reuptake inhibitors-resistant major depressive disorder (Kondo et al., 2011; Lyoo et al., 2012) . Noteworthy, our study clearly extends literature data by showing that besides producing a synergistic antidepressant action with fluoxetine, creatine also exerts this effect with paroxetine, citalopram and sertraline, a finding that may have therapeutic implication.
It is known that depression is common in the context of autoimmune and inflammatory diseases and is frequently associated with persistently raised levels of proinflammatory cytokines and other markers of inflammation (Maes et al., 2012) . Of note, 5-HT inhibits the proinflamatory cytokine TNF-␣ production (Cloëz-Tayarani et al., 2003) and WAY100635 and 8-OH-DPAT markedly enhanced the antidepressant effect of fluoxetine at the subeffective dose on the interferon-␣-treated mice in the forced swimming test (Zhang et al., 2010) . In addition, creatine is also able to reduce plasma proinflammatory cytokines levels (interleukin-1␤, interleukin-6, tumor necrosis factor-␣ and interferon-␣) in an inflammatory condition (after a half-ironman competition), suggesting an antiinflamatory property of creatine. Then, a possibility to account for our results is that creatine supplementation may modulate inflammatory parameters via the serotonergic system, a hypothesis that needs future investigation.
Taking into account that we have previously shown that the antidepressant-like effect of creatine is mediated by dopaminergic activation (Cunha et al., 2012) and considering that fluoxetine seems to influence the dopaminergic neurotransmission (Penttilä et al., 2004) , we also cannot rule out the possibility that an interaction of the serotoninergic and dopaminergic systems could play a role in the antidepressant-like effect of creatine.
Conclusions
In conclusion, the results presented herein indicate that the antidepressant-like action of creatine seems to be mediated by a stimulation of the post-synaptic 5-HT 1A receptors and an inhibition of presynaptic 5-HT 1A autoreceptors. Therefore, we suggest that creatine could be used alone or in combination with antidepressant compounds in depression associated with hyposerotonergic dysfunction. Although the results presented here should be taken with care, they warrant future work focusing on the hypothesis that a combination of creatine with selective serotonin reuptake inhibitors can be helpful in treating depressive patients.
